Coherus BioSciences saw sales of its Udenyca (pegfilgrastim-cbqv) biosimilar in the US rocket once again in the second quarter, after continued strong momentum for its February launch of an on-body rival to Amgen’s Neulasta.
Coherus Enjoying Pegfilgrastim Revival As Amgen Royalty Dues Expire
Firm Has Three Pronged-Plan, Confident Udenyca Biosimilar Growth Will Continue In 2024
Coherus BioSciences has seen a seismic jump in sales of, and market share for, its US biosimilar pegfilgrastim franchise. The firm is optimistic that the momentum will continue through the year.
More from Earnings
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.